The estimated Net Worth of Michael Andrew Schemick is at least $18.4 million dollars as of 31 March 2023. Michael Schemick owns over 13,302 units of Certara stock worth over $5,791,412 and over the last 5 years Michael sold CERT stock worth over $12,564,665.
Michael has made over 8 trades of the Certara stock since 2019, according to the Form 4 filled with the SEC. Most recently Michael exercised 13,302 units of CERT stock worth $146,056 on 31 March 2023.
The largest trade Michael's ever made was selling 66,667 units of Certara stock on 18 October 2021 worth over $2,432,012. On average, Michael trades about 43,830 units every 135 days since 2019. As of 31 March 2023 Michael still owns at least 527,451 units of Certara stock.
You can see the complete history of Michael Schemick stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman et Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: